1 Title: Multiple Introductions of Mpox virus to Ireland during the 2022 International

2 Outbreak

3

9

- 4 **Authors:** Gabriel Gonzalez, ^{1,2,3} Michael Carr, ^{1,3} Tomás M. Kelleher, ¹ Emer O'Byrne, ¹
- Weronika Banka, Brian Keogan, Charlene Bennett, Geraldine Franzoni, Patrice Keane,
- 6 Luke W. Meredith, Nicola Fletcher, 5,6 Jose Maria Urtasun-Elizari, Jonathan Dean, Brendan
- 7 Crowley, ⁴ Derval Igoe, ⁷ Eve Robinson, ⁷ Greg Martin, ⁷ Jeff Connell, ¹ Cillian F. De Gascun, ¹
- 8 Daniel Hare¹
- 10 Affiliations
- ¹ UCD National Virus Reference Laboratory, University College Dublin, Belfield, D04
- 12 E1W1, Ireland
- ² Japan Initiative for World-leading Vaccine Research and Development Centers, Hokkaido
- 14 University, Institute for Vaccine Research and Development, Hokkaido 001-0021, Japan
- ³ International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido
- 16 University, Sapporo, Hokkaido 001-0020, Japan
- ⁴Department of Virology, St. James's Hospital, Dublin, Ireland
- ⁵ Veterinary Sciences Centre, University College Dublin, Belfield, D04 E1W1, Ireland
- ⁶ Centre for Experimental Pathogen Host Research, University College Dublin, Belfield, D04
- 20 E1W1, Ireland

23

- ⁷ Health Protection Surveillance Centre, Ireland
- ⁸ Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- 24 **Correspondence:** Daniel Hare (daniel.hare@ucd.ie)

26

Abstract

27 **Background:** mpox (formerly Monkeypox) virus (MPXV) was considered a rare zoonotic 28 disease prior to May 2022, when a global epidemic of cases in non-endemic countries led to 29 the declaration of a Public Health Emergency of International Concern. Previously, mpox 30 infection was associated with symptoms similar to smallpox, although substantially less 31 severe, including fever, an extensive characteristic rash and swollen lymph nodes. 32 **Aim:** Elucidating the origin and molecular characteristics of the virus circulating in the 33 Republic of Ireland in the period between May and November 2022. 34 Methods: Whole-genome sequencing of all MPXV cases (80%; n=178/219) analysed against sequences from public databases (n=2695). Bayesian approaches were used to infer the 35 36 divergence time between sequences from different subclades and transmission events 37 involving different countries. 38 **Results:** The circulating virus belonged to the clade IIb B.1 lineage and, notably, the 39 presence of twelve separable and highly-supported subclades consistent with multiple 40 introductions into the country. Such a hypothesis of multiple importation events was 41 supported further by the estimation of the time to the divergence of subclades. Additionally, 42 inferred MPXV transmissions involving different countries and continents were indicative of 43 an extended international spread. The analysis of the mutations in the Irish sequences 44 revealed 93% of the mutations were from cytosine to thymine (or from guanine to adenine), 45 leading to a high number of non-synonymous mutations across the subclades. 46 **Conclusion:** In the context of extremely high national sequencing coverage, we provide new 47 insights into the international origin and transmission dynamics supporting multiple 48 introductions into the Republic of Ireland. 49 50 **Keywords:** mpox virus, monkeypox virus, genome, epidemiological analysis, epidemic 51 dynamics. 52 53 **Conflict of Interests.** 54 None to declare. 55

56 Introduction 57 Mpox (Monkeypox) virus (MPXV) is a double-stranded DNA virus in the genus 58 Orthopoxvirus within the Poxviridae family (Xiang and White, 2022) and is regarded as a 59 High consequence Infectious Agent (HCID). Despite its name, the natural reservoir of the 60 virus remains unknown but it is transmitted among small mammals, such as rodents (W.H.O., 61 2023). The length of the MPXV genome is approximately 197.2 kb encoding a predicted 191 62 proteins, and is genetically closely related to the variola (smallpox) virus. Mpox symptoms 63 can last between two and four weeks and include fever, sore throat, headache, muscle aches, 64 low energy, swollen lymph nodes and rash; however, the combination and severity of these 65 symptoms varies among patients and some severe cases can develop skin lesions (Saxena et 66 al., 2023). The virus is transmitted to humans by direct contact with infected animals, through 67 scratches and bites, or materials, such as contaminated clothes or needles, or by contact with 68 lesions of infected people. Sexual transmission appears to be a major route of transmission, in 69 particular during the recent outbreak, (W.H.O., 2023; Sun et al., 2023). 70 Two major clades of MPXV have been recognised as circulating endemically in 71 Africa, one in Central Africa (clade I) and the other one in West Africa (clade II) with 72 differing transmissibility and case fatality rates (Quarleri et al., 2022). In this context, an 73 increased number of cases started appearing internationally in May 2022, and were 74 characterised as part of the West African clade II. Based on viral phylogenetic properties and 75 epidemiological evidence of increased human-to-human transmission outside of endemic 76 geographic locations, MPXV cases in the context of the 2022 outbreak were classified within 77 a distinct subclade, termed IIb (Gigante et al., 2022). The outbreak has been reported across 78 multiple countries on different continents and has differed from earlier outbreaks of clade I 79 and IIa, in terms of host age (54.3% of individuals in their thirties), sex (predominantly male), 80 and sexual transmission the most commonly reported (Bragazzi et al., 2023). The overall case fatality rate of mpox has been estimated at 8.7%, though substantial 81 82 differences have been observed between clades: estimated as 10.6% for clade I, versus 1-83 3.6% for clade IIa (Bunge et al., 2022; Americo et al., 2023), and a mortality rate in the range 84 0.01-1.81% for Clade IIb associated with the 2022 event (Reda et al., 2022). Whilst the 2022 85 international outbreaks of MPXV clade IIb had milder clinical severity, therefore, it 86 represented a significant public health concern due to the significant increase in reported 87 sexual transmission and concerns regarding "spill over" into other more susceptible 88 populations (Sun et al., 2023; Borges et al., 2023). Due to the unprecedented nature of the 89 mpox epidemic outbreaks outside endemic African countries and its classification as an

HCID, the WHO declared a Public Health Emergency of International Concern (PHEIC) in

July 2022 (Wenham and Eccleston-Turner, 2022).

MPXV clade case designation by genomic analyses facilitates an evidence-based assessment of transmissibility and the ability to distinguish new importation events. To establish a comprehensive genomic epidemiological baseline for national surveillance in the Republic of Ireland, whole-genome sequencing (WGS) was performed at the National Virus Reference Laboratory for all available MPXV laboratory-confirmed positive cases. Genome sequences (n=178 sequences) were obtained covering an extremely high percentage (>80% of cases) of all cases between May and November 2022 (n=219 cases). This comprehensive MPXV genomic dataset was analysed further to elucidate the dynamics of the 2022 MPXV epidemic in the Republic of Ireland to ascertain whether single or multiple introductions of the virus were responsible.

102

103

104

105

106

107

108

109

110

111

112

113114

115

116

117

118

119

120

121122

123

124

125

126

127

128

129

130

131

132133

134

135

Materials & Methods Sample collection. Samples (predominantly swabs of skin lesions/pustules transported in virus transport media, VTM)) were received from 219 symptomatic individuals who presented for medical attention. Following lysis and inactivation in a Containment Level 3 (CL3) facility with a VTM to guanidinium isothiocyanate lysis buffer mixed in a ratio of 1:2.5, total nucleic acids were extracted on the Roche MagNA Pure 96 platform as follows: 200 µL of swab material in VTM was added to 500 µL Roche lysis buffer, and, following external lysis, were extracted on the Roche MagNA Pure 96 system (input volume 450 μL and eluted in 100 μL). Alternatively, DNA from 200 µL of material in VTM was extracted using the Qiagen QIAamp DNA Mini kit, according to the manufacturer's instructions. Molecular Diagnostics. Real-time PCR was performed on the ABI7500 SDS platform employing initially the pan-Orthopoxvirus zoonotic (non-variola) RT-PCR kit (Altona); for logistical reasons the assay was switched to the MPXV generic assay described by Li et al. (Li et al., 2010). However, a CDC notification of a rare but significant deletion in the target TNF gene motivated to change the assay to the LDT pan-Orthopoxvirus assay currently in use (Schroeder and Nitsche, 2010). Whole-Genome Sequencing. MPXV qPCR positive samples were processed for WGS following a tiled amplicon approach and next-generation sequencing (NGS) approach employing Oxford Nanopore Technologies (ONT). Tiled amplicons were generated from each sample employing two separate MPXV primer pools (P/N 50025, MBS), according to the manufacturer's instructions (Matthijs Welkers et al., 2022). Amplicons were barcoded employing the Rapid Barcoding Kit 96 (SQK-RBK110.96; ONT) and loaded onto a R9.4.1 flow cell (FLO-MIN106D; ONT) with 23 samples and a negative control on each run. The data generated were basecalled and demultiplexed with Guppy v5.1.13 (ONT). The sequence reads were trimmed to remove adapters and barcoded sequences with Porechop v.0.3.2pre (https://github.com/rrwick/Porechop). NGS reads were assembled employing a MPXV genome sampled in November of 2021 in the United States of America (GenBank ON676708) as the reference. The assembled consensus genome sequences were deposited in GenBank (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers OR146268-

136

137

138

139

140

141

142

143

144

145

146 147

148

149

150

151

152

153

154

155

156

157

158159

160

161

162

163

164 165

166

167

168

169

OR146445 and also in GISAID (Supplementary Table S2). MPXV clades were assigned following the automatic assignment by GISAID after data submission. All multiple sequence alignments (MSA) were performed with MAFFT by the algorithm FFT-NS-1 (Katoh et al., 2019). Phylogenies were inferred using a maximumlikelihood (ML) approach with RAxML using the general time reversible (GTR) substitution model and support for the branches was estimated with a bootstrap approach considering 500 repetitions (Stamatakis, 2014). MSA included ON676708 as reference to annotate the coding regions and to analyse the effects of the nucleotide mutations as amino acid substitutions in the encoded proteins with only mutations on nucleotides supported by sequence depth > 20reads analysed further. Inferring time to the most recent common ancestor. The divergence times of the different MPXV subclades to the most recent common ancestor (tMRCA) were inferred using BEAST2 v2.5.7 (Bouckaert et al., 2019). The reference ON676708 was employed as an outgroup for rooting the tree. The substitution model was chosen using the model test in RAxML GUI (Edler et al., 2021) and the Bayesian information criterion (BIC), choosing the Hasegawa-Kishino-Yano (HKY) substitution model as the best fit for the sequences requiring the least amount of parameters with a proportion of invariant sites (+I). The different models with a constant clock or an uncorrelated Optimised Relaxed Clock (ORC) (Douglas et al., 2021), with the population modelled either as constant size, exponential growth or Bayesian skyline, were considered and compared to identify the most likely model among the six combinations. All models were calibrated with the collection date of the samples. Each model was executed for 10⁸ steps sampling every 10⁴ to assure an Effective Sample Size (ESS) > 100 for all parameters in the models, i.e. the number of effectively independent draws for each parameter from the posterior distribution that the Markov chain was equivalent to. The model parameters were summarised and explored with Tracer 1.7.1, and tree of the best model was summarised using the 'treannotator' programme in the BEAST bundle to extract the divergence time and the mutation rate of the subclades. Testing association with international MPXV genome sequences. Contemporaneous sequences were downloaded from the MPXV database in GISAID (https://gisaid.org/) with the filtering criteria requiring near complete genome sequences and high quality (>90% genome coverage) (Supplementary Table S1). Additionally, reference

sequences from previous MPXV outbreaks were downloaded from GenBank (Supplementary

170

171

172

173

174

175

176

177

178

179180

181

182

183 184

185

186

187

Table S1). The association of Irish genome sequences to sequenced cases from other countries was tested by separating the group of Irish sequences into the following twelve IIb subclades: B.1, B.1.1, B.1.2, B.1.3, B.1.5, B.1.7, B.1.8, B.1.9, B.1.10, B.1.11, B.1.12, and B.1.15. The MSAs of these groups included GISAID sequences from the same subclades to test the phylogenetic relationships and putative origins of the MPXV with the Bayesian inference approach of Outbreaker2 (Campbell et al., 2018), using the collection date reported in GISAID and assuming an infectious period of 28 days with the highest probability of transmission between days 6 and 15, following the description of cases and transmission via skin lesions (W.H.O., 2023). The assumed mutation rate was 5×10^{-5} , the lower end of the mutation rate range from the BEAST analysis. The Outbreaker2 inference was run for 10⁶ steps in each of the eleven groups, with 10% burn-in and sampling every 2500 steps. Among the Outbreaker2 results of transmissions, we considered as evidence of transmission between two samples those links with support > 0.3 and suggesting less than two generations. Ethical approval. The analysis of the data was approved by the University College Dublin Human Research Ethics Committee - Sciences analysed data with the Research Ethics Reference Number: LS-LRSD-23-197-Gonzalez-Hare.

Results

Characteristics of the 2022 MPXV outbreak. The 219 laboratory-confirmed MPXV qPCR-positive samples analysed in the present study were collected between May and November 2022. As reported by the Health Service Executive (HSE) of the Republic of Ireland (ROI), the majority of cases were males with a median age of 35 years with 79.8% aged between 18-44 years (HPSC, 2023). These cases were distributed over time with the peak in August (> 60 cases) (Fig. 1).





Figure 1. MPXV cases reported in the Republic of Ireland. The horizontal and vertical axes represent the epidemiological week of 2022 when the samples were received and the total number of reported cases across the country, respectively. The distribution of subclades assigned by GISAID has been coloured according to the legend. Months are shown on the top of the panel.

WGS of Irish MPXV in 2022. Among the 219 cases, 178 (80%) were successfully sequenced, of which 175 met the ≥90% coverage threshold with an average genome coverage of 99.3 ± 2% (Supplementary Table S2). The high coverage of the sequences facilitated the mutational analysis compared to the MPXV clade IIb reference genome ON676708, which was chosen as reference. The transition/transversion ratio was 22.8, with 286 positions showing mutations relative to the reference genome. Of the total number of mutations, 47% and 46% were transitions C to T and G to A, respectively (Supplementary Table S3). Relative to the reference genome annotation, these mutations were approximately seven times more frequent in coding regions than in the non-coding regions (Supplementary Table S4). Moreover, 154 mutations were non-synonymous mutations while 100 were synonymous mutations with 32 characterised as non-coding mutations (Supplementary Table S4). These

mutations distributed into the different GISAID-assigned clades as follows: a total of 11 mutations were considered common to all sequenced samples with their presence in >90% of the sequenced samples; 194 mutations were identified as isolated single nucleotide variants (SNV) present in only one sequence, among them, 132 (n=105) were in the IIb B.1 subclade (dark green sequences in Fig. 2). Conversely, a total of 104 SNVs were distributed and characteristic to each subclade (Fig. 2), i.e. common to all the sequences under the same subclade in the format IIb B.1.* as follows - B.1.1: 6 SNV (n=6), B.1.2: 20 (n=9), B.1.3: 10 (n=11), B.1.5: 7 (n=2), B.1.7: 27 (n=28), B.1.8: 8 (n=1), B.1.9: 5 (n=2), B.1.10: 13 (n=6), B.1.11: 4 (n=1), B.1.12: 2 (n=3), and B.1.15: 2 (n=1). The remaining 28 mutations corresponded to variants within each subclade. These SNV have accumulated following divergence among subclades and point mutations were still accumulating, as was most evident in the basal subclade IIb B.1.



213

214

215

216

217

218

219

220 221

222

Figure 2. The MPXV phylogenetic tree for whole-genome sequences of Irish cases and reference genomes. The tree was rooted with an MPXV Clade I sequence (GISAID acc. number: EPI_ISL_13058460) and other reference sequences were added to corroborate the clade assignments for the sequences. All external sequences show the corresponding accession number and short description of their origin. Support for branching nodes, estimated with a bootstrap approach (500 repetitions), is shown for support \geq 70%. Tip names have been coloured according to the subclade as shown on the colour legend. The scale of the tree represents 5×10^{-4} mutations per nucleotide site.

The subclades assigned by GISAID, the number of characteristic mutations per subclade, and the phylogenetic relationships among our samples and sequences from previous outbreaks confirmed the identity of the cases as belonging to the MPXV clade IIb B.1 (Fig. 2). Furthermore, at least twelve phylogenetically separable and highly-supported subclades were suggested to circulate simultaneously in ROI during the 2022 epidemic (Fig. 2). The cases identified during the outbreak belonged to the subclade IIb B.1, however, during the 20 weeks period when these cases were detected, distinct variants were identified suggesting at least two alternative hypotheses to explain these findings: (i) the twelve subclades were introduced to ROI in a single initial wave that evolved locally, or (ii) a flow of new subclades to the country in multiple separate importation events.

Dating the divergence of the Irish MPXV subclades. To investigate further the possible origins of the multiple subclades circulating in ROI, the divergence times of the different subclades were inferred employing a Bayesian approach. The comparison of the considered Bayesian models demonstrated that a combination of a Bayesian skyline modelling of the population growth with an uncorrelated relaxed clock was the model with the highest likelihood for the observed genomic data (Table 1). The dating of the tMRCA of the different subclades to mid-May (2022.37, 95% HPD [2022.28, 2022.40], corresponding to epidemiological weeks 15 and 21 of 2022, respectively) was consistent with divergence prior to the outbreaks in the ROI (Table 1, Fig. 3). This also provided evidence in support of the hypothesis that multiple introductions, not a single importation event, of new and diverse variants into Ireland occurred throughout the 2022 outbreak event. Furthermore, while other phylogenetic groups were observed to have diverged as early as the last week of May, at least two clades, namely IIb B.1.9 and B.1.12, diverged in August 2022 and, given that no earlier cases assigned to these clades were detected, it is considered more likely they were introduced into the country later in the course of the outbreak. Additionally, other subclusters in IIb B.1 and B.1.2 are suggested to have diverged after August and as late as

September 2022 (Fig. 3). It is noteworthy that despite the best fit being a Bayesian skyline with the ORC, all the inferred models had very similar dates for the tMRCA and relatively high mutation rates in the range [7.2E-5, 1.3E-4] which is notably higher than the 10⁻⁶ mutation rate previously reported for the family *Orthopoxviruses* (Babkin et al., 2022).




Figure 3. Bayesian inferred phylogenetic tree with the most likely time of the MRCA for the different clades in the Republic of Ireland. The circular tree represents the 175 ROI sequences rooted with ON676708 (IIb A.1). The nodes show the most likely day of the year 2022 for the MRCA, the scale for these days and the corresponding months are shown as blue concentric circles. Clades are coloured as in Fig. 2 and have been added to the tip names for reference.

Table 1. Comparison of Bayesian models and the inferred time to the MRCA of the MPXV clades in the Republic of Ireland.

	Bayesian Model to Estimate time of the MRCA									
	Population	Constant Size	Constant Size	Exponential Growth	Exponential Growth	Bayesian skyline	Bayesian skyline	Week (Month)		
	Molecular clock	Strict Clock	ORC	Strict Clock	ORC	Strict Clock	ORC			
Mutation Rate		1E-4	1E-4	1E-4	1E-4	9.6E-5	9.4E-5			
95% HPDI		[7.7E-5, 1.2E-4]	[7.4E-5, 1.4E-4]	[7.6E-5, 1.3E-4]	[7.2E-5, 1.3E-4]	[7.8E-5, 1.1E-4]	[7.2E-5, 1.2E-4]			
Likelihood		-266137	-266087	-266138	-266086	-266126	-266073			
Date of MRCA	IIb B.1	2022.18	2022.04	2022.20	2022.15	2022.37	2022.37	W20		
95% HPDI		[2021.63, 2022.33]	[2021.66, 2022.27]	[2022.05, 2022.30]	[2021.93, 2022.29]	[2022.31, 2022.40]	[2022.28, 2022.4]	(16-22 May)		
	IIb B.1.1	2022.43	2022.43	2022.43	2022.43	2022.42	2022.42	W22		
		[2022.38, 2022.45]	[2022.36, 2022.45]	[2022.39, 2022.45]	[2022.37, 2022.45]	[2022.39, 2022.45]	[2022.39, 2022.45]	(30 May - 05 June)		
	IIb B.1.2	2022.43	2022.45	2022.44	2022.45	2022.42	2022.42	W22		
		[2022.35, 2022.48]	[2022.37, 2022.49]	[2022.35, 2022.48]	[2022.38, 2022.49]	[2022.39, 2022.45]	[2022.39, 2022.46]	(30 May - 05 June)		
	IIb B.1.3	2022.37	2022.35	2022.37	2022.36	2022.40	2022.40	W21		
		[2022.30, 2022.41]	[2022.23, 2022.41]	[2022.31, 2022.41]	[2022.27, 2022.41]	[2022.38, 2022.41]	[2022.38, 2022.41]	(23-29 May)		
	IIb B.1.5	2022.29	2022.40	2022.30	2022.40	2022.41	2022.42	W22		
		[2022.15, 2022.40]	[2022.20, 2022.45]	[2022.16, 2022.41]	[2022.27, 2022.45]	[2022.39, 2022.44]	[2022.40, 2022.45]	(30 May - 05 June)		
	IIb B.1.7	2022.38	2022.41	2022.39	2022.42	2022.41	2022.41	W22		
		[2022.26, 2022.45]	[2022.27, 2022.46]	[2022.27, 2022.45]	[2022.30, 2022.46]	[2022.38, 2022.43]	[2022.38, 2022.44]	(30 May - 05 June)		
	IIb B.1.9	2022.63	2022.62	2022.62	2022.62	2022.62	2022.62	W31		
		[2022.60, 2022.63]	[2022.60, 2022.63]	[2022.59, 2022.63]	[2022.58, 2022.63]	[2022.60, 2022.63]	[2022.58, 2022.63]	(01-07 August)		
	IIb B.1.10	2022.41	2022.41	2022.42	2022.42	2022.42	2022.42	W22		
		[2022.34, 2022.45]	[2022.31, 2022.46]	[2022.35, 2022.46]	[2022.35, 2022.46]	[2022.39, 2022.44]	[2022.39, 202245]	(30 May - 05 June)		
	IIb B.1.12	2022.61	2022.60	2022.60	2022.59	2022.61	2022.60	W32		
		[2022.56, 2022.63]	[2022.54, 2022.63]	[2022.54, 2022.63]	[2022.52, 2022.63]	[2022.57, 2022.63]	[2022.52, 2022.63]	(08-14 August)		

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

Uncovering possible origins of the MPXV introductions to Ireland. As mentioned above, the clade IIb subclade B.1 was predominant during the 2022 MPXV outbreak in ROI (n=105), and consistent with the distribution in other locations for the same time period with between 33% and 74% of sequences from this subclade (Table 2). As some of the other circulating subclades were suggested to have diverged some time prior to the first MPXV case detected in the ROI (31 May 2022), the subclade sequences were compared with sequences from other geographical locations to identify putative origins for the different clades and to explore further the evidence for any transmission events within these individuals (Fig. 4, Supplementary Fig. S1 and Supplementary Fig. S2). Despite the conservative approach used to infer the transmission, requiring less than two generations and a support of > 30% in the Outbreaker2 inference, many nodes were connected across the different countries and continents, reflecting the international transmission dynamics. Many of the inferred infectious links supported the transmission between cases from the same geographical location as community transmission in IIb B.1.9 and B.1.10 (Supplementary Fig. S2C-D) or the more numerous cases in IIb B.1.1, B.1.2 and B.1.7 (Supplementary Fig. S1A, B, D). The Bayesian analysis inferred strong support for importation events based on the collection dates and phylogenetic relationships among the sequences. The inference suggested importations into ROI from both Europe (United Kingdom, Portugal, Germany, Switzerland) and North and South America (the United States of America, Colombia, and Brazil) (Fig. 4).




Figure 4. Summary of inferred transmissions among countries detected in the subclades detected in the Republic of Ireland. The nodes represent countries where the lineages of subclades in the clade IIb B.1 were sequenced. The size of the nodes reflects the number of sequences reported by each country. The arrows represent the direction of inferred transmission events.

Table 2. MPXV clade IIb subclades in GISAID from the 2022 outbreak.

Subclades	Location									
	Ireland	Europe	North America	South America	Asia	Oceania	Cases			
IIb B.1	60%	74%	60%	61%	33%	100%	1874			
IIb B.1.1	3%	7%	4%	22%	11%		217			
IIb B.1.2	5%	3%	12%	2%	22%		195			
IIb B.1.3	6%	3%	4%		26%		102			
IIb B.1.5	1%	3%	1%		4%		56			
IIb B.1.7	16%	4%	5%	1%	4%		137			
IIb B.1.8	1%	2%	3%				51			
IIb B.1.9	1%	1%	0%	4%			31			
IIb B.1.10	3%	1%	0%	8%			50			
IIb B.1.11	1%	0%	5%	1%			65			
IIb B.1.12	2%	1%	4%	1%			50			
IIb B.1.15	1%	1%	0%	1%			14			
Cases	175	1253	1074	312	27	1				

306

307

308 309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

Discussion The first detections of MPXV in Ireland was notified on May 31st 2022 with the earliest onset of symptoms on May 13th. The major peak of cases was in and August 2022 and declined significantly since this time. A similar observation has been shared in other jurisdictions where the numbers of cases have decreased significantly worldwide. The explanation for the decline in case numbers is likely multifactorial including effective public health communication regarding protective measures, the subsequent introduction of safe practices to mitigate against transmission in vulnerable groups. Parallel with this the introduction of targeted vaccination policy to protect those at most risk and the reduced mass gathering events in late 2022 (HSE, 2022; Yang et al., 2023). The smallpox vaccine was offered as MPXV prophylaxis and it has been suggested that the previous cessation of the smallpox vaccination around the world could have been one of the factors contributing to the emergence of the current outbreak (Bunge et al., 2022). Since the 2022 outbreak in the ROI described here, there have been further sporadic cases (n=5) notified in December 2022, January 2023 and August 2023, and internationally a surge of cases in East Asia during July and August (Murphy, 2023). This indicates importation events are likely occurring with the potential for onward transmission. Such cases highlight the need for vigilance, early detection with timely genomic surveillance and rapid public sharing of sequences to monitor for potential amino acid substitutions and for MPXV clade changes over time on both national and international levels. The availability of the large genomic epidemiological baseline from 2022 described in this study will facilitate the delineation of transmission patterns and, specifically, the ability to distinguish imported from autochthonous transmission events as the priority must be to mitigate against further disease transmission by preventing the establishment of recalcitrant reservoirs arising from potential silent transmission, i.e. in asymptomatic cases (Mizushima et al., 2023), in different geographical regions which will seed further outbreaks. Our results of MPXV genomic epidemiological analysis demonstrates multiple introductions of the virus to the ROI with evidence for continued divergence during 2022. Such results were consistent with the national published reports documenting that 50.9% (n=116/190) of cases were associated with a recent history of international travel in the 21 days prior to symptom onset (HPSC, 2023). Our analyses also contextualised the Irish cases into the global genomic epidemiology of the unprecedented international MPXV 2022 outbreak (Isidro et al., 2022), with the presence of subclades with higher prevalence in

different continents suggested to be transmitted to cases in Ireland.

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

The dominant clade of circulating MPXV in Ireland was suggested to accumulate mutations at a rate that was at least an order of magnitude higher than previously reported (Babkin et al., 2022), which is in keeping with recent data from a number of other studies (Yadav et al., 2022; Luna et al., 2022). The Bayesian-inferred population model suggested an increase in the effective population size early on in the outbreak that gave origin to many of the different subclades, as a probable consequence of the extensive human-to-human transmission events and adaptation and modification by the human host immune response (Yang et al., 2023). Such results could explain the distinctive pattern of the increases in the number of accumulated mutations as the virus was replicating and being transmitted. The analysis of mutational patterns amongst our MPXV cases strongly supported the hypothesis that much of this divergence is driven by the effects of enzymes of the APOBEC cytosine deaminase family where C to T (or G to A on the lagging strand) mutations predominated (Isidro et al., 2022), as was also observed in the evolution of SARS-CoV-2 during the COVID-19 pandemic (Mourier et al., 2021). Therefore, while MPXV may still be considered a zoonotic infection (W.H.O., 2023), viral phylogenetic and Bayesian analysis of local and international transmission dynamics provide evidence in support of sustained adaptation of the virus to the human and a potential risk to public health by altered transmission (Yang et al., 2023; Luna et al., 2022) The extremely high sequencing coverage in our study facilitated robust phylogenetic inferences to be drawn by reducing uncertainty as to the direction and dating of the transmission between cases. With lower national genomic surveillance, uncertainty increases and the number of possible transmission routes and epidemiological variables also grows exponentially. As a consequence, this limits the amount of information that can be drawn from the gathered data. The combination of epidemiological data with high sequencing coverage for a particular outbreak can lead to insights into the origins, the transmission dynamics and even susceptibility of different populations as was implemented during the COVID-19 pandemic in tracing the epidemiological dynamics of SARS-CoV-2 (Lucey et al., 2021; Hare et al., 2021). In conclusion, through detailed phylogenetic analysis of MPXV cases, in the context of extremely high sequencing coverage by international comparison performed in the Irish population, we provide evidence for multiple introductions during the 2022 outbreak underscoring the possibility that importation events could recur here and elsewhere posing a continued threat to public health. This dataset provides an epidemiological baseline to monitor future MPXV importation events by analogy to that employed for other pathogen

genomics efforts including influenza, measles and polio. The surveillance of MPXV genetic diversity also enables the assessment of the effectiveness of interventions to contain epidemic threats and the rational development of target-specific prophylactic vaccines. Furthermore, with a better understanding of the nature of MPXV introductions into Ireland, and their subsequent transmission dynamics, evidence based public health interventions can be planned and implemented, and mathematical modelling of mpox epidemiology can inform vaccination policy.

Acknowledgements

 We gratefully acknowledge all authors from reference laboratories who submitted genome sequences to public databases. This study was partially supported by AMED under the grant number JP223fa627005.

Contributions

Gabriel Gonzalez: data analysis and draft manuscript preparation; Michael Carr: genome sequencing and manuscript edition; Tomás M. Kelleher: genome sequencing; Emer O'Byrne: sample extraction, genome sequencing and manuscript edition; Weronika Banka: sample extraction, genome sequencing and manuscript edition; Brian Keogan: sample location and extraction, manuscript edition; Charlene Bennett: protocols validation; Geraldine Franzoni: protocols validation; Patrice Keane: genome sequencing and manuscript edition; Luke W. Meredith: genome sequencing protocol; Nicola Fletcher: genome sequencing and manuscript edition; Jose Maria Urtasun-Elizari: sequence analysis and manuscript preparation; Jonathan Dean: data collection and analysis, manuscript edition; Brendan Crowley: sample collection, results validation and manuscript edition; Derval Igoe: data evaluation and manuscript edition; Eve Robinson: data evaluation and manuscript edition; Derval Edition; Daniel Hare: study oversight, manuscript preparation; Cillian F. De Gascun: study oversight, manuscript preparation. All authors reviewed the results and approved the final version of the manuscript.

References

- 406 Xiang, Y.; White, A. Monkeypox virus emerges from the shadow of its more infamous
- 407 cousin: family biology matters. Emerg Microbes Infect. 2022 Dec;11(1):1768-1777.
- 408 W.H.O. Mpox (monkeypox) Fact sheet; [modified 18-04-2023; cited 2023 28-07-2023].
- 409 Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox
- 410 Saxena, S.K.; Ansari, S.; Maurya, V.K.; Kumar, S.; Jain, A.; Paweska, J.T.; Tripathi, A.K.;
- 411 Abdel-Moneim, A.S. Re-emerging human monkeypox: A major public-health debacle. J Med
- 412 Virol. 2023 Jan;95(1):e27902.
- 413 Sun, Y.Q.; Chen, J.J.; Liu, M.C.; Zhang, Y.Y.; Wang, T.; Che, T.L.; Li, T.T.; Liu, Y.N.;
- 414 Teng, A.Y.; Wu, B.Z.; Hong, X.G.; Xu, Q.; Lv, C.L.; Jiang, B.G.; Liu, W.; Fang, L.Q.
- 415 Mapping global zoonotic niche and interregional transmission risk of monkeypox: a
- retrospective observational study. Global Health. 2023 Aug 17;19(1):58.
- 417 Quarleri, J.; Delpino, M.V.; Galvan, V. Monkeypox: considerations for the understanding and
- 418 containment of the current outbreak in non-endemic countries. Geroscience. 2022
- 419 Aug;44(4):2095-2103.
- 420 Gigante, C.M.; Korber, B.; Seabolt, M.H.; Wilkins, K.; Davidson, W.; Rao, A.K.; Zhao, H.;
- Smith, T.G.; Hughes, C.M.; Minhaj, F.; Waltenburg, M.A.; Theiler, J.; Smole, S.; Gallagher,
- 422 G.R.; Blythe, D.; Myers, R.; Schulte, J.; Stringer, J.; Lee, P.; Mendoza, R.M.; Griffin-Thomas,
- 423 L.A.; Crain, J.; Murray, J.; Atkinson, A.; Gonzalez, A.H.; Nash, J.; Batra, D.; Damon, I.;
- 424 McQuiston, J.; Hutson, C.L.; McCollum, A.M.; Li, Y. Multiple lineages of monkeypox virus
- detected in the United States, 2021-2022. Science. 2022 Nov 4;378(6619):560-565.
- Bragazzi, N.L.; Kong, J.D.; Mahroum, N.; Tsigalou, C.; Khamisy-Farah, R.; Converti, M.;
- 427 Wu, J. Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A
- preliminary pooled data analysis and literature review. J Med Virol. 2023 Jan;95(1):e27931.
- Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The
- changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS
- 431 Negl Trop Dis. 2022 Feb;16(2):e0010141.
- 432 Americo, J.L.; Earl, P.L.; Moss, B. Virulence differences of mpox (monkeypox) virus clades
- I, IIa, and IIb.1 in a small animal model. Proc Natl Acad Sci U S A. 2023 Feb
- 434 21;120(8):e2220415120.
- 435 Reda, A.; Hemmeda, L.; Brakat, A.M.; Sah, R.; El-Qushayri, A.E. The clinical manifestations
- and severity of the 2022 monkeypox outbreak among 4080 patients. Travel Med Infect Dis.
- 437 2022 Nov-Dec;50:102456.
- Borges, V.; Duque, M.P.; Martins, J.V.; Vasconcelos, P.; Ferreira, R.; Sobral, D.; Pelerito,
- 439 A.; de Carvalho, I.L.; Nuncio, M.S.; Borrego, M.J.; Roemer, C.; Neher, R.A.; O'Driscoll, M.;
- 440 Rocha, R.; Lopo, S.; Neves, R.; Palminha, P.; Coelho, L.; Nunes, A.; Isidro, J.; Pinto, M.;
- 441 Santos, J.D.; Mixao, V.; Santos, D.; Duarte, S.; Vieira, L.; Martins, F.; Machado, J.;
- Verissimo, V.C.; Grau, B.; Peralta-Santos, A.; Neves, J.; Caldeira, M.; Pestana, M.;
- Fernandes, C.; Caria, J.; Pinto, R.; Povoas, D.; Maltez, F.; Sa, A.I.; Salvador, M.B.; Teofilo,
- E.; Rocha, M.; Moneti, V.; Duque, L.M.; FF, E.S.; Baptista, T.; Vasconcelos, J.; Casanova,
- 445 S.; Mansinho, K.; Alves, J.V.; Alves, J.; Silva, A.; Alpalhao, M.; Brazao, C.; Sousa, D.;
- 446 Filipe, P.; Pacheco, P.; Peruzzu, F.; de Jesus, R.P.; Ferreira, L.; Mendez, J.; Jordao, S.; Duarte,
- F.; Goncalves, M.J.; Pena, E.; Silva, C.N.; Guimaraes, A.R.; Tavares, M.; Freitas, G.;
- 448 Cordeiro, R.; Gomes, J.P. Viral genetic clustering and transmission dynamics of the 2022
- mpox outbreak in Portugal. Nat Med. 2023 Sep 11.
- Wenham, C.; Eccleston-Turner, M. Monkeypox as a PHEIC: implications for global health
- 451 governance. Lancet. 2022 Dec 17;400(10369):2169-2171.
- 452 Li, Y.; Zhao, H.; Wilkins, K.; Hughes, C.; Damon, I.K. Real-time PCR assays for the specific
- detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods.
- 454 2010 Oct;169(1):223-227.

- 455 Schroeder, K.; Nitsche, A. Multicolour, multiplex real-time PCR assay for the detection of
- human-pathogenic poxviruses. Mol Cell Probes. 2010 Apr;24(2):110-113.
- 457 Matthijs Welkers; M. Jonges; Ouden, A.v.d. onkeypox virus whole genome sequencing using
- combination of NextGenPCR and Oxford Nanopore V.1; [cited 2023]. Available from:
- https://www.protocols.io/private/974ACB78F83911EC998C0A58A9FEAC02
- Katoh, K.; Rozewicki, J.; Yamada, K.D. MAFFT online service: multiple sequence alignment,
- 461 interactive sequence choice and visualization. Brief Bioinform. 2019 Jul 19;20(4):1160-1166.
- Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
- 463 phylogenies. Bioinformatics. 2014 May 1;30(9):1312-1313.
- Bouckaert, R.; Vaughan, T.G.; Barido-Sottani, J.; Duchene, S.; Fourment, M.; Gavryushkina,
- 465 A.; Heled, J.; Jones, G.; Kuhnert, D.; De Maio, N.; Matschiner, M.; Mendes, F.K.; Muller,
- N.F.; Ogilvie, H.A.; du Plessis, L.; Popinga, A.; Rambaut, A.; Rasmussen, D.; Siveroni, I.;
- 467 Suchard, M.A.; Wu, C.H.; Xie, D.; Zhang, C.; Stadler, T.; Drummond, A.J. BEAST 2.5: An
- advanced software platform for Bayesian evolutionary analysis. PLoS Comput Biol. 2019
- 469 Apr;15(4):e1006650.
- 470 Edler, D.; Klein, J.; Antonelli, A.; Silvestro, D. raxmlGUI 2.0: A graphical interface and
- 471 toolkit for phylogenetic analyses using RAxML. Methods in Ecology and Evolution.
- 472 2021;12(2):373-377.
- Douglas, J.; Zhang, R.; Bouckaert, R. Adaptive dating and fast proposals: Revisiting the
- phylogenetic relaxed clock model. PLoS Comput Biol. 2021 Feb;17(2):e1008322.
- 475 Campbell, F.; Didelot, X.; Fitzjohn, R.; Ferguson, N.; Cori, A.; Jombart, T. outbreaker2: a
- 476 modular platform for outbreak reconstruction. BMC Bioinformatics. 2018 Oct 22;19(Suppl
- 477 11):363.
- 478 HPSC. Epidemiological characteristics of confirmed mpox cases in Ireland; May 2022 to
- February 2023 Republic of Ireland: HPSC; [modified April 2023; cited 2023 28-07-2023].
- 480 Available from:
- 481 https://ndsc.newsweaver.ie/4otaa688p3/18ojfxozmu1?lang=en&a=1&p=62869572&t=31302
- 482 978
- Babkin, I.V.; Babkina, I.N.; Tikunova, N.V. An Update of Orthopoxvirus Molecular
- 484 Evolution. Viruses. 2022 Feb 14;14(2).
- 485 HSE. Update on HSE monkeypox vaccination programme; [cited 2023 2023-08-15].
- 486 Available from: https://www.hse.ie/eng/services/news/media/pressrel/update-on-hse-
- 487 <u>monkeypox-vaccination-programme.html</u>
- 488 Yang, S.; Guo, X.; Zhao, Z.; Abudunaibi, B.; Zhao, Y.; Rui, J.; Wang, Y.; Song, W.; Wei, H.;
- 489 Chen, T. Possibility of mpox viral transmission and control from high-risk to the general
- 490 population: a modeling study. BMC Infect Dis. 2023 Feb 24;23(1):119.
- 491 Murphy, F. Mpox: China's health authorities fight surge in cases of unknown origin. BMJ.
- 492 2023 Aug 22;382:1939.
- 493 Mizushima, D.; Shintani, Y.; Takano, M.; Shiojiri, D.; Ando, N.; Aoki, T.; Watanabe, K.;
- Nakamoto, T.; Gatanaga, H.; Oka, S. Prevalence of Asymptomatic Mpox among Men Who
- 495 Have Sex with Men, Japan, January-March 2023. Emerging Infectious Diseases. 2023;29(9).
- 496 Isidro, J.; Borges, V.; Pinto, M.; Sobral, D.; Santos, J.D.; Nunes, A.; Mixao, V.; Ferreira, R.;
- Santos, D.; Duarte, S.; Vieira, L.; Borrego, M.J.; Nuncio, S.; de Carvalho, I.L.; Pelerito, A.;
- 498 Cordeiro, R.; Gomes, J.P. Phylogenomic characterization and signs of microevolution in the
- 499 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022 Aug;28(8):1569-1572.
- Yadav, P.; Devasurmutt, Y.; Tatu, U. Phylogenomic and Structural Analysis of the
- 501 Monkeypox Virus Shows Evolution towards Increased Stability. Viruses. 2022 Dec 31;15(1).
- 502 Luna, N.; Ramirez, A.L.; Munoz, M.; Ballesteros, N.; Patino, L.H.; Castaneda, S.A.; Bonilla-
- Aldana, D.K.; Paniz-Mondolfi, A.; Ramirez, J.D. Phylogenomic analysis of the monkeypox

- virus (MPXV) 2022 outbreak: Emergence of a novel viral lineage? Travel Med Infect Dis.
- 505 2022 Sep-Oct;49:102402.
- Mourier, T.; Sadykov, M.; Carr, M.J.; Gonzalez, G.; Hall, W.W.; Pain, A. Host-directed
- editing of the SARS-CoV-2 genome. Biochem Biophys Res Commun. 2021 Jan 29;538:35-
- 508 39

- 509 Lucey, M.; Macori, G.; Mullane, N.; Sutton-Fitzpatrick, U.; Gonzalez, G.; Coughlan, S.;
- Purcell, A.; Fenelon, L.; Fanning, S.; Schaffer, K. Whole-genome Sequencing to Track
- 511 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in
- Nosocomial Outbreaks. Clin Infect Dis. 2021 Jun 1;72(11):e727-e735.
- Hare, D.; Gonzalez, G.; Dean, J.; McDonnell, K.; Carr, M.J.; De Gascun, C.F. Genomic
- 514 epidemiological analysis of SARS-CoV-2 household transmission. Access Microbiol.
- 515 2021;3(7):000252.